We are a Canadian contract development and manufacturing organization (CDMO) specializing in the production of nucleic acid and lipid products that support life-enabling work. We strive towards this daily by developing and deploying our state-of-the-art bioprocessing and chemical process technologies, using proprietary manufacturing and analytical approaches, employing a highly skilled workforce, and partnering with an excellent and extensive network of relationships and collaborations. We support our customers by providing scalable manufacturing capacity and help them accelerate innovation in bringing their products from benchtop to bedside or field. We are dedicated to supporting our customers by providing scalable manufacturing capacity and accelerating innovation in bringing their products from the benchtop to real-world applications.

We CARE. We CREATE. We DELIVER. The driving philosophy behind LTS LOHMANN Therapie-Systeme AG. As a trusted technology partner for the pharmaceutical industry, we develop and manufacture innovative drug delivery systems such as Transdermal Patches (“TTS”) and Oral Thin Films (“OTF”) as well as wearable drug delivery devices (“OBDS”). LTS´ commercial offering encompasses more than 20 marketed products and a diverse pipeline of more than 40 development projects targeting multiple disease indications. LTS’s innovation pipeline contains both partner-funded and proprietary, LTS-funded projects. With its SorrelTM wearable drug delivery platform LTS offers patient friendly solutions for complex drugs delivery at home. To learn more, please visit www.ltslohmann.com

Nanite is a next-generation non-viral gene delivery company developing a new class of programmable polymer nanoparticles for a range of modalities and indications. The company’s AI-driven platform, SAYER, combines cutting-edge high-throughput experimental and computational methods to design fit-for-purpose delivery vehicles delivering a broad range of genetic cargoes with tissue specificity. For more information, visit: https://www.nanitebio.com/

Based in the U.S., Lifecore Injectables CDMO has expertise in formulation, filtration, aseptic filling, and packaging of complex injectable pharmaceuticals and medical devices. With 20+ commercial products and a proven 40+ year regulatory history, we work with early-to-late-stage programs to provide process development, clinical and commercial manufacturing, and expansive, on-site analytical services including stability. To learn more, please visit https://www.lifecore.com/

Elligo Health Research accelerates clinical trials through EHR data, our proprietary IntElligo® technology, and direct access to known, diverse patients from more than 115 hospitals and major health systems, 200 healthcare-based sites, and 100 research-based sites. Our PatientSelect® model engages our network of networks to optimize the intersection of healthcare and research and bring more patients clinical research as a care option. Our SiteSelect model and Research Partner Services enable sites to seamlessly participate in trials, further advancing the development of new pharmaceutical, biotechnology, and medical device and diagnostic products. For more information, go to https://www.elligohealthresearch.com/.

Merxin Ltd: We Make Inhalers. We make dry powder inhalers (DPI) and soft mist inhalers (SMI). Our range of soft mist, dry powder and multidose dry powder inhalers are ready to launch your molecules. Our capsule DPI MRX003 is on the market; our SMI MRX004 is the preferred option for both biologics and ultra-low carbon footprint; MRX006 is a multidose “open-inhaler-close” DPI; MRX002 is a see through cannister for HFA/HFO pMDI formulations. We Will Launch You. For more information, please visit www.MERXIN.com. 

With more than 70 years’ experience in medical devices, Owen Mumford Pharmaceutical Services is a division of Owen Mumford, with the Head Office located in Woodstock, UK. Our global presence spans from manufacturing facilities in the UK and Malaysia to subsidiaries in the US, Germany and France. Owen Mumford Pharmaceutical Services specializes in the design, development and manufacture of injectable drug delivery systems for the pharmaceutical, biotech and generics industries. Our trusted devices are used daily in the delivery of various medications for a multitude of conditions across the globe. Our product portfolio includes single and multi-dose reusable and disposable auto-injectors, pens, and syringes for subcutaneous and intramuscular administration. Our flagship products include UniSafe® platform, a spring-free, passive safety device for 1ml and 2.25ml pre-filled syringes. UniSafe 1mL has regulatory approval as a combination product in Asia and Europe where it is also in patient use. Our most recent innovation is the 2-step disposable auto-injector Aidaptus®. Aidaptus can be used for both 1mL and 2.25mL syringes in the same base device. It can also readily adapt to different fill volumes using auto-adjust plunger technology providing a solution for formulation changes during development and lifecycle management. We are proud to have been awarded a distinction in the prestigious Red Dot awards for innovative product design 2023 for Aidaptus. For more information, visit https://www.ompharmaservices.com/

Firak Consulting Group is a boutique consulting firm that focuses on bringing patient inclusive strategies to pharma, biopharma, and patient advocacy groups. To learn more, please visit www.firakconsulting.com.

At Publicis Health, we are united around one purpose: to create a world where people are equipped and motivated to take control of their health. We transform healthcare marketing and communications into clinical trial engagement. We believe healthcare marketing is healthcare, fostering healthy conversations, healthy behaviors and healthy people. For more information, go to https://publicishealth.com/companies

Heartbeat Clinical Research is leading the shift from patient recruitment to patient activation. Traditional recruitment is about filling a funnel. Patient activation is about building a movement. Through Activate™, we empower patients to take control of their health journey—not as passive participants, but as informed advocates. We don’t just reach communities; we work within them, co-creating with patients, building trust, and making research a natural extension of care.

Born from the union of BBK Worldwide and Langland U.S., Heartbeat brings decades of expertise in creative storytelling and data-driven strategy to reshape how clinical research connects with people. Our approach blends behavioral science, grassroots engagement, and real-world insights to break down barriers and create lasting networks of activation. When patients are truly empowered, research doesn’t just enroll them—it belongs to them.

At Heartbeat, we’re not fixing an old system. We’re building a new one—where patients lead the way.

To learn more please visit: https://weareheartbeat.com/clinical-research

Medable is on a mission to get effective therapies to people faster. Its AI-powered clinical trials platform enhances speed, scale, and patient access in clinical research, accelerating medicines for thousands of conditions without treatment or cure. Named a Leader in the industry by Everest Group and awarded Best Digital Health Solution by the Galien Foundation, the Medable platform has been deployed in more than 300 trials in 60 countries and 120 languages, serving more than one million patients globally. Medable is a privately held, venture-backed company headquartered in Palo Alto, California, and ranked #398 on the Inc. 5000 in 2023. For more information, go to https://www.medable.com/